Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.58 |
| ▸ | JAK2 | O60674 | 8/20 | 0.37 |
| ▸ | JAK3 | P52333 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.37 |
| ▸ | JAK1 | P23458 | 6/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338717 | 1.00 | RIPK1 (0.58) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL25816769 | 0.85 | RIPK1 (0.64) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL30338822 | 0.85 | RIPK1 (0.64) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL25294541 | 0.85 | RIPK1 (0.46) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL30338797 | 0.85 | RIPK1 (0.46) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL25263315 | 0.81 | RIPK1 (0.52) | RIPK1JAK2JAK3KMO | |
| Trifluoroacetic Acid SCHEMBL30338968 | 0.80 | RIPK1 (0.60) | RIPK1JAK2JAK3KMO | |
| SCHEMBL25296950 | 0.79 | RIPK1 (0.47) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL30338977 | 0.79 | RIPK1 (0.47) | RIPK1JAK2JAK3KCNH2JAK1 | |
| SCHEMBL30339228 | 0.79 | RIPK1 (0.64) | RIPK1JAK2JAK3KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | claimed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | claimed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885JAK2 583/4885JAK3 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.